Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Interpreting 2 recent studies involving Alzheimer disease

Ron Louie, MD
Conditions
April 27, 2019
136 Shares
Share
Tweet
Share

Two prestigious medical journals published studies involving Alzheimer disease (AD) and amyloid beta in successive weeks; both were paired with guest expert commentaries (editorials).  One editorial, about a drug study, also reviewed several other failures in anti-amyloid therapy and stated: “To be blunt, A-beta [amyloid] lowering seems like an ineffective approach….” The other editorial had an encouraging attitude toward amyloid PET imaging as part of the diagnostic process for dementia, but it left me with questions about conclusions.

The NEJM reports a newer trial of verubecestat, a drug that improved target amyloid imaging and biomarkers, but seemed to make subjects worse, had side effects, and essentially failed to improve endpoints.  This trial is interesting because it recruited subjects earlier in their disease process than seen in most other studies, i.e. it tested those labeled as “prodromal,” rather than the “mild-to-moderate” subjects previously reported.

Last year’s FDA guidance to Pharma, for those seeking accelerated approval for dementia drugs, discussed recruiting early patient cohorts. It addressed the notion that numerous AD therapeutic failures were due to the patients selected, perhaps too advanced to be salvaged, even ones clinically designated as “mild.” With early subjects, however, there is a risk of damaging relatively healthy people and affecting their quality of life even when their dementia prognosis might be uncertain.

The NEJM guest editorialist, Dr. D. Knopman from Mayo, discusses the study but also provides context with a concise review of the “amyloidogenic pathway” so strongly associated with AD.  There is an instructive illustration.  He reviews multiple possible points of attack on amyloid, and the target points in recent therapeutic failures.  His full concluding statement is: “To be blunt, lowering A-beta [amyloid] seems to be an ineffective approach, and it is time to focus on other targets to move therapeutics for Alzheimer’s disease forward.”

The JAMA reports a study of dementia specialists’ clinical actions after they were provided a report on their patients’ amyloid PET imaging. The patients already had a diagnosis of progressive Mild Cognitive Impairment or Dementia of uncertain etiology. The authors state that amyloid PET scans (even with various agents) are specific to a very high degree, but can be positive in other neurodegenerative conditions and even in cognitively normal older folks; scans were scored here as either positive or negative.

The study shows that dementia specialists’ clinical management will change for about 2/3 of their patients (60 to 64 percent) after a scan. The authors do not provide any patient outcome data in this report [expected later], but AD drug prescriptions increased overall. The drugs prescribed are not considered disease-modifying or anti-amyloid.

Strictly speaking, using an old definition, AD is diagnosed with brain tissue under the microscope.  The authors state that the presence of amyloid is required, but not sufficient, for neuropathology diagnosis. Since brain biopsies are evidently not routine, amyloid PET can act as a surrogate for tissue examination.  Negative scans might be particularly helpful, to avoid giving AD drugs (whose only FDA indication is for “dementia of the Alzheimer type”) to those who probably don’t have AD. Yet AD drugs were continued in those with negative scans, and new ones were even given to some patients with negative scans.

Amyloid PET scans were evidently under reimbursement review by Medicare when the JAMA study was initiated.  For context, FDG-PET scans for cancer had to go through a multi-year process before limited indication approval for payment. National organizations like the ABIM and ASCO discuss the rational use of expensive scans through their “Choosing Wisely” guidelines.

The JAMA guest commentators, Drs. C. Jack and R. Peterson, are coincidentally from Mayo.  Dr. Jack is the first author of a significant “research framework” position paper last year, proposing that neuroimaging including PET scans for amyloid beta and tau be the foundation of AD and dementia research going forward, even re-defining “Alzheimer’s Disease” itself based on their “AT(N)” paradigm.

Even though unresolved questions, including pathophysiology, evidently prompted the research framework paper, the following comments concluded their editorial: “Given the evidence provided by the IDEAS [JAMA] study that more specific knowledge provided by biomarkers about etiology of impairment was associated with changes in short-term clinical management, a path forward seems apparent. More detailed etiologic characterization by deeper biomarker-based phenotyping will result in more precise, patient-specific management decision making. Ultimately, the hope is that management will include access to pathophysiologically appropriate, disease-modifying interventions.”

My oncologist (non-neurologist) questions about the JAMA study: 1) The authors of the study recognize several limitations and mention this: when an enrollment criterion requires that participants agree that “knowledge of amyloid PET status was expected to alter diagnosis and management,” doesn’t this create a foregone conclusion? 2) What are the pressures on prescribing physicians to “do something” when they are given results of an imaging test, given the “pent-up clinical demand” cited by the editorial? How many prescriptions would there be without access to scans?  3) Is the word “etiology,” implying certain knowledge of the primary cause in AD, the right word for the protocol and editorialists to use? Could amyloid deposition be akin to scar tissue?

The JAMA study also reminded me of “The Will Rogers Phenomenon,” a type of lead time bias, seen in cancer studies when new imaging techniques are introduced, and how that might influence survival statistics.  Will that kind of phenomenon influence the eventual report and interpretation of patient outcomes from this cohort?

Ron Louie is a pediatric oncologist.

Image credit: Shutterstock.com

Prev

4 reasons why this physician specialized in infectious disease

April 27, 2019 Kevin 0
…
Next

Pause before writing your personal statement

April 28, 2019 Kevin 0
…

Tagged as: Neurology

Post navigation

< Previous Post
4 reasons why this physician specialized in infectious disease
Next Post >
Pause before writing your personal statement

More by Ron Louie, MD

  • Will Alzheimer’s disease researchers miss seeing the forest from the trees?

    Ron Louie, MD
  • Do substituted decisions break the Golden Rule?

    Ron Louie, MD
  • Dementia patients want effective drugs. How will the FDA respond?

    Ron Louie, MD

Related Posts

  • Should only infectious disease specialists be allowed to prescribe antibiotics?

    Craig Bowron, MD
  • The culture of perfection in medicine is a disease

    Andy Cruz, MD
  • HIPAA case studies: misguided mistakes and egregious errors

    Michael J. Sacopulos, JD
  • Chronic disease is making medical education worse

    Jason J. Han, MD
  • The recent fish oil and vitamin D studies: Go beyond the headlines

    Mary Chris Jaklevic
  • Health care workers should not be targets

    Lori E. Johnson

More in Conditions

  • Emotional journey: An inspiring tale from the operating room in Nicaragua

    David Alfery, MD
  • How modern lifestyle changes are disrupting our immune systems

    Kara Wada, MD
  • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

    Harvey Max Chochinov, MD, PhD
  • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

    Hoag Memorial Hospital Presbyterian
  • The rising threat of lung cancer in Asian American female nonsmokers

    Alice S. Y. Lee, MD
  • Urgent innovation needed to address growing mental health crisis among children and families

    Monika Roots, MD
  • Most Popular

  • Past Week

    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions
    • Revealing America’s expansion: the dark truth of Native American suffering and unjustified abuses

      Anonymous | Physician
    • Georgia’s new law promoting truth and transparency in health care credentials

      Carmen Kavali, MD | Policy
    • The tragic story of Mr. G: a painful journey towards understanding suicide

      William Lynes, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Proactive risk management: a game-changer in preventing physician burnout

      Howard Smith, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
  • Recent Posts

    • Emotional journey: An inspiring tale from the operating room in Nicaragua

      David Alfery, MD | Conditions
    • Physician excellence: Transitioning from the comfort zone to the growth zone for exceptional patient care

      Harvey Castro, MD, MBA | Physician
    • Pursuing undergrad research without misrepresenting your career path

      Paris H. Grey and David G. Oppenheimer, PhD | Education
    • How healthy eating can protect us from extreme weather

      R. Jason Newsom, MD, MPH | Policy
    • Unfilled residency spots and the future of emergency medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • How excessively regulating doctors can harm patients

      Richard Gunderman, MD, PhD and James Lynch, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Was Kratom Linked With Lethal Arrhythmias?
  • Ultrasound for Distal Forearm Fractures in Kids; Ketamine vs ECT for Depression
  • Are Engineering and Medicine Good Bedfellows?
  • Poor Nutrition Status Linked With Survival After MitraClip
  • Hooray! A Clearer Estimate of Your Risk for Death Is Around the Corner

Meeting Coverage

  • Poor Nutrition Status Linked With Survival After MitraClip
  • Transapical Transcatheter Mitral Valve Replacement Trial Raises Questions
  • MitraClip Shines in Real-World, Core-Lab Data
  • Risankizumab Safe in Older Crohn's Disease Patients
  • How to Better Identify HER2-Low Breast Cancer
  • Most Popular

  • Past Week

    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions
    • Revealing America’s expansion: the dark truth of Native American suffering and unjustified abuses

      Anonymous | Physician
    • Georgia’s new law promoting truth and transparency in health care credentials

      Carmen Kavali, MD | Policy
    • The tragic story of Mr. G: a painful journey towards understanding suicide

      William Lynes, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Proactive risk management: a game-changer in preventing physician burnout

      Howard Smith, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
  • Recent Posts

    • Emotional journey: An inspiring tale from the operating room in Nicaragua

      David Alfery, MD | Conditions
    • Physician excellence: Transitioning from the comfort zone to the growth zone for exceptional patient care

      Harvey Castro, MD, MBA | Physician
    • Pursuing undergrad research without misrepresenting your career path

      Paris H. Grey and David G. Oppenheimer, PhD | Education
    • How healthy eating can protect us from extreme weather

      R. Jason Newsom, MD, MPH | Policy
    • Unfilled residency spots and the future of emergency medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • How excessively regulating doctors can harm patients

      Richard Gunderman, MD, PhD and James Lynch, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...